Nephrectomy (RN) is the current standard of care for large organ confined renal tumors while Partial Nephrectomy (PN) is recommanded for tumor sizes up to 7 cm. PN preserves long term renal function with possible effect on overall survival. Axitinib, a potent VEGFR TKI can reduce the size of primary tumor in metastatic setting. Our primary objective was to test the ability of axitinib to reduce the size of large tumors for shifting from a RN to a PN indication.
INTRODUCTION AND OBJECTIVES: Laparoscopic Radical
Nephrectomy (RN) is the current standard of care for large organ confined renal tumors while Partial Nephrectomy (PN) is recommanded for tumor sizes up to 7 cm. PN preserves long term renal function with possible effect on overall survival. Axitinib, a potent VEGFR TKI can reduce the size of primary tumor in metastatic setting. Our primary objective was to test the ability of axitinib to reduce the size of large tumors for shifting from a RN to a PN indication.
METHODS: Patients with localized (cT2N0M0) RCCs were enrolled in a prospective phase II trial assessing the effect of neoadjuvant axitinib prior to surgery (PN or RN). Main inclusion criteria were: age 18, histologically proven clear cell RCC, MDRD creatinin clearance 60 ml/min, cT2a N0NxM0 tumors (&[null] > 7cm; 10 cm). Medical treatment consisted in axitinib 5 mg up to 10 mg tw/d during 2 to 6 months prior surgery according to radiological response.
RESULTS: A total of 18 patients including 11 men (61%) and 7 women (39%) with a median age of 60 yrs were enrolled. Median baseline tumor size, RENAL score, serum creatinine and MDRD estimated GFR were: 7.6 cm, 11, 0.8 mg/dl and 96.5 ml/min respectively. Duration of treatment was 2, 4 and 6 months in 12 (66%), 3 (17%) and 3 cases (17%), respectively. Median interval from treatment stop to surgery was 6 days. After neoadjuvant treatment median tumor size and RENAL score decreased to 6.2 cm and 10. 89% of patients presented a decrease in maximum tumor diameter, with median size reduction of 19%. Out of the 17 patients who were operated, 16 (94%) underwent a PN (9 robotic & 7 open), including 67% of the cases which were performed for tumors 7cm. At 1 month from surgery, median serum creatinin and MDRD estimated GFR were 0.9 mg/dl and 87 ml/min, respectively. Medical and surgical complications included 1 embolization for severe bleeding and 1 Clavien V complication at 1 month after surgery due to massive myocardial infarction.
CONCLUSIONS: Neoadjuvant axitinib in cT2 renal tumors allowed cT1 downstaging and nephron sparing surgery in almost 70% of the cases. However, PN procedures remained high complexity cases requiring adequate surgeon expertise and information of the patients for possible morbidity of these procedures.
Source of Funding: none

MP72-20 DIFFERENTIAL HEMODYNAMIC AND ANTIHYPERTENSIVE CHANGES AFTER PARTIAL NEPHRECTOMY VERSUS RADICAL NEPHRECTOMY
Ryan Hutchinson*, Nirmish Singla, Laura-Maria Krabbe, Solomon Woldu, Gong Chen, Charles Rew, Isamu Tachibana, Yair Lotan, Jeffrey A. Cadeddu, Vitaly Margulis, Dallas, TX INTRODUCTION AND OBJECTIVES: Partial nephrectomy is a common therapy for small renal masses and is associated with improved postoperative renal function when compared to radical nephrectomy. The highest quality prospective study of partial versus radical nephrectomy demonstrated worse overall survival in patients undergoing partial nephrectomy which appeared to be driven by cardiovascular outcomes. We examined patients undergoing partial and radical nephrectomy to assess for possible differential postsurgical hemodynamic effects.
METHODS: An institutional renal mass database was queried for patients undergoing partial or radical nephrectomy between 2006 and 2012. Serial blood pressure followup, clinicopathologic variables and changes in medications including antihypertensives were collected. Patients were excluded for inadequate data, non-curative-intent surgery, non-cancer surgical indication and absence of medication information. Time-dependent changes in blood pressure were compared by split-plot ANOVA and addition or modification of antihypertensive regimen were studied as time-to-event survival analyses with Kaplan-Meier curves and a Cox proportional hazards model. RESULTS: Between 2006 and 2012, 402 partial nephrectomies and 205 radical nephrectomies were performed and a final cohort of 264 partial nephrectomy and 130 radical nephrectomy cases was identified with evaluable data. Patients undergoing partial nephrectomy were significantly younger, more likely to have T1 tumors, and had lower preoperative creatinine values (p < 0.001 for all). No differences were noted on postoperative systolic blood pressures, diastolic blood pressures and heart rates (p > 0.05) however, these analyses were underpowered on post-hoc analysis. Significantly more patients who underwent partial nephrectomy started new antihypertensive medications postoperatively (p ¼ <0.001) and surgical treatment remained as a significant independent predictor on multivariate Cox regression (HR 2.51, p ¼ 0.002).
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THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 CONCLUSIONS: Hemodynamic parameters after radical or partial nephrectomy may be different. The etiology of this observation, if any, is currently unexplored. Additional prospective mechanistic investigations are warranted. 
Source of Funding: None
INTRODUCTION AND OBJECTIVES:
Immune checkpoint inhibitors-based therapy is rapidly developing into an effective treatment option for a surprising range of cancers. Despite the autoimmune or inflammatory immune-mediated adverse effects which have been seen, the responses and overall survival benefits exhibited thus far warrant further clinical development. Lycorine, an alkaloid extracted from plants in the Amaryllidaceae family, which showed a strong anticancer effect by inducing cell lysis of various carcinomas. This study investigated the effectiveness of a combination therapy of lycorine and anti-CTLA-4 in a mouse model of renal cell carcinoma (RCC).
METHODS: We investigated the anti-tumor efficacy of lycorine in various RCC cell lines including Caki-1, ACHN, KPK-1 and Renca through XTT proliferation, scratch motility, migration and invasion assays. We also discuss that mechanism underlying this anticancer potential with flow cytometry and western blot. Furthermore, luciferase-expressing Renca cells were implanted in the left kidney and the lung of BALB/c mice to develop a RCC metastatic mouse model for investigated the combination therapy effect of lycorine and anti-CTLA-4.
RESULTS: We confirmed the anticancer potential of lycorine in vitro as observed time-dependent inhibition in several RCC cell lines. Moreover, lycorine suppressed the migratory and invasive abilities of Renca cells. The possible mechanism underlying this anticancer potential was cell cycle profile arrest. Lycorine and anti-CTLA-4 additively decreased tumor weight, lung metastasis, and luciferin-stained tumor images. Importantly, these effects were dependent on significantly suppressing regulatory T-cells while upregulating effector T-cells.
CONCLUSIONS: Herein, as we know, it's the first report that lycorine in combination with anti-CTLA-4 inhibited orthotopic and metastatic tumors by downregulating Treg, which was accompanied with upregulation of effector T-cells. Our findings suggest and indicate lycorine as a potent candidate for treating RCC and will serve as an excellent aid for developing a better treatment strategy for the use of immune checkpoint inhibitors in RCC. METHODS: We extracted 109 TILs from 80 patients who underwent surgical resection of RCC, of which 44 TILs were multiply extracted from 15 patients. Each TIL was characterized on the basis of functional T-cell populations using 10 surface marker expressions measured by flow cytometry. Immunological classification was performed by unsupervised clustering analysis of TILs. Comparisons between the surface marker expressions and clinical features were evaluated by logistic regression analysis. Distributions of overall metastasis free survival (MFS) time and recurrence free survival (RFS) was estimated with Kaplan-Meier method and immunological classification was assessed with the log-rank test.
Source of
RESULTS: All of the TILs were classified into three groups, which correlated significantly with a substantial number of TILs (p<0.001) and the population of circulating T-cell subsets. Also 35 patients (81.4%) within Group III had lower Fuhrman Grade tumor (G1, 2) whereas 19 patients (47.5%) within Group I, II had higher Fuhrman Grade tumor (G3, 4) (p¼0.028). In multivariate analysis, only Fuhrman grade was also significantly correlated with this immunological classification (odds ratio: 0.253, 95% Confidence Interval (CI): 0.094-0.678, p¼0.006). Importantly, this classification was significantly correlated with overall MFS (hazard ratio (HR): 0.449, 95% CI: 0.243-0.832, p¼0.011) and RFS (HR: 0.475, 95%CI: 0.238-0.948, p¼0.035) in multivariate analysis. Also, we discovered the presence of intra-tumoral diversity in the classification of 3 (20%) of the 15 patients.
CONCLUSIONS: This study showed the presence of classable diversity in the immunological signature of TILs correlated with tumor aggressiveness and prognosis that is observed even within the individual tumor in some patients with RCC.
